← Back to Clinical Trials
Recruiting Phase 2 NCT03582917

NCT03582917 The Role of VitD in Rehabilitation of Idiopathic Adolescent Scoliosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03582917
Status Recruiting
Phase Phase 2
Sponsor University of Ioannina
Condition Scoliosis; Adolescence
Study Type INTERVENTIONAL
Enrollment 80 participants
Start Date 2018-09-20
Primary Completion 2025-12-20

Eligibility & Interventions

Sex All sexes
Min Age 10 Years
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
Alphacalcidol

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.

This trial targets 80 participants in total. It began in 2018-09-20 with a primary completion date of 2025-12-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this current prospective study is to determine the role of vitamin D in the development and restoration of spinal deformities in adolescence.

Eligibility Criteria

Inclusion Criteria: * Idiopathic Adolescent Scoliosis * Risser sign \<3-4 Exclusion Criteria: * Neuromuscular diseases * metabolic disease * Liver, lung, thyroid and parathyroid gland disorders.

Contact & Investigator

Central Contact

Lazaros Tagkalidis

✉ akissdoc@hotmail.com

📞 +30 6977252028

Frequently Asked Questions

Who can join the NCT03582917 clinical trial?

This trial is open to participants of all sexes, aged 10 Years or older, up to 18 Years, studying Scoliosis; Adolescence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT03582917 trial and what does that mean for participants?

Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.

Is NCT03582917 currently recruiting?

Yes, NCT03582917 is actively recruiting participants. Contact the research team at akissdoc@hotmail.com for enrollment information.

Where is the NCT03582917 trial being conducted?

This trial is being conducted at Asvestochóri, Greece, Ioannina, Greece.

Who is sponsoring the NCT03582917 clinical trial?

NCT03582917 is sponsored by University of Ioannina. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology